Insider buying · SEC Form 4

SCTX insider buying

Open-market purchases of Scribe Therapeutics Inc. (SCTX) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

3insider buys on record
$56.3Mbought in total
3different insiders
0by CEOs, CFOs and other chiefs
Jul 30, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
Jul 30, 2026Carl L. GordonDirector$15.0M1,000,000$15.00New stakeJul 29, 2026
Form 4 ↗
IPO purchase at $15.00/share; SCTX now $18.36 (+22.4% since buy). Gordon is a Partner at OrbiMed Advisors; companion Form 4 also filed by OrbiMed Advisors LLC (accession 0000947871-26-000733) for the same transaction. Part of a $56M+ cluster buy at the SCTX IPO alongside Avoro/Aghazadeh ($36M, filed July 28) and Andreessen Horowitz ($5M).
Jul 30, 2026Marc L. Andreessen10% Owner / Venture Investor (Andreessen Horowitz)$5.00M333,333$15.00New stakeJul 29, 2026
Form 4 ↗
IPO purchase at $15.00/share via AH Bio Fund II, L.P.; filing also names Ben Horowitz. SCTX now $18.36 (+22.4% since buy). a16z also received 2,749,392 shares from preferred-stock conversions (AH Bio Funds II & III). Stock ran to $22.31 on first trading day before pulling back to $18.36.
Jul 29, 2026Behzad Aghazadeh / Avoro Capital Advisors LLC / Avoro Ventures LLCDirector / 10% Owner$36.3M2,391,238$15.16New stakeJul 28, 2026
Form 4 ↗
IPO allocation of 2,333,333 shares at $15.00 ($35.0M from underwriters, ~July 24 IPO) plus post-IPO open-market: 50,000 shares at $22.31 and 7,905 shares at $18.25. Current price $18.06 (+20.4% vs IPO price; -17.7% vs avg open-market buy of ~$21.93). Gene-editing / CRISPR biotech; Aghazadeh sits on board.

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.